AR069860A1 - Metodo para purificar un anticuerpo cd20 - Google Patents

Metodo para purificar un anticuerpo cd20

Info

Publication number
AR069860A1
AR069860A1 ARP080105605A ARP080105605A AR069860A1 AR 069860 A1 AR069860 A1 AR 069860A1 AR P080105605 A ARP080105605 A AR P080105605A AR P080105605 A ARP080105605 A AR P080105605A AR 069860 A1 AR069860 A1 AR 069860A1
Authority
AR
Argentina
Prior art keywords
antibody
purifying
mixture
hccf
recovering
Prior art date
Application number
ARP080105605A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR069860A1 publication Critical patent/AR069860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Abstract

La mezcla consistiendo en un fluido celular cosechado concentrado (HCCF) de un cultivo celular recombinante que produce el anticuerpo CD20, no ha sido sometida a liofilizacion previa. También se proveen cristales de un anticuerpo CD20, una composicion farmacéutica y un método de tratamiento de una enfermedad o afeccion asociada a CD20. Reivindicacion 1: Un método para purificar un anticuerpo CD20 de una mezcla, caracterizado porque comprende cristalizar el anticuerpo CD20 y recuperar el anticuerpo CD20 de la mezcla.
ARP080105605A 2007-12-21 2008-12-19 Metodo para purificar un anticuerpo cd20 AR069860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1628807P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
AR069860A1 true AR069860A1 (es) 2010-02-24

Family

ID=40347971

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105605A AR069860A1 (es) 2007-12-21 2008-12-19 Metodo para purificar un anticuerpo cd20

Country Status (15)

Country Link
US (1) US20110020322A1 (es)
EP (1) EP2235056A1 (es)
JP (1) JP2011507870A (es)
KR (1) KR20100105720A (es)
CN (1) CN101945890A (es)
AR (1) AR069860A1 (es)
AU (1) AU2008343347A1 (es)
BR (1) BRPI0820604A2 (es)
CA (1) CA2708951A1 (es)
CL (1) CL2008003790A1 (es)
IL (1) IL206227A0 (es)
PE (1) PE20091337A1 (es)
RU (1) RU2010130467A (es)
TW (1) TW200932758A (es)
WO (1) WO2009085765A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN101577344B (zh) * 2009-06-11 2011-04-20 珠海银通交通能源投资有限公司 动力电池
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
EP2846830A1 (en) * 2012-05-11 2015-03-18 Novartis AG Crystallization methods for purification of monoclonal antibodies
KR101941742B1 (ko) * 2012-06-21 2019-01-23 신톤 바이오파머슈티칼즈 비.브이. 항체의 정제 방법
US10293106B2 (en) * 2013-04-03 2019-05-21 Becton, Dickinson And Company Intravenous tubing set modified for in-line catheter flushing
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
DK3083689T3 (da) 2013-12-17 2020-08-03 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
AU2017361081A1 (en) 2016-11-15 2019-05-23 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IT202100004496A1 (it) 2021-02-25 2022-08-25 Univ Della Calabria Recupero di farmaci biologici o loro frammenti da soluzioni impure mediante cristallizzazione o precipitazione con membrane

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5509070A (en) * 1992-12-15 1996-04-16 Softlock Services Inc. Method for encouraging purchase of executable and non-executable software
US6134659A (en) * 1998-01-07 2000-10-17 Sprong; Katherine A. Controlled usage software
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)

Also Published As

Publication number Publication date
KR20100105720A (ko) 2010-09-29
WO2009085765A1 (en) 2009-07-09
RU2010130467A (ru) 2012-01-27
US20110020322A1 (en) 2011-01-27
CL2008003790A1 (es) 2010-02-05
JP2011507870A (ja) 2011-03-10
CN101945890A (zh) 2011-01-12
PE20091337A1 (es) 2009-09-03
AU2008343347A1 (en) 2009-07-09
EP2235056A1 (en) 2010-10-06
CA2708951A1 (en) 2009-07-09
IL206227A0 (en) 2010-12-30
BRPI0820604A2 (pt) 2017-05-09
TW200932758A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
ES2541217T3 (es) Diferenciación de células madre mesenquimales
ES2542853T3 (es) Método para tratar miastenia grave
MX2019004254A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones, y procesos, relacionados a las mismas.
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
CL2011000207A1 (es) Composicion biocida que comprende ciprodinil y flutianil; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n°2602-06).
BR112012012460A8 (pt) método de liofilização, composições e kits
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
ECSP109956A (es) Composiciones y métodos para controlar nemátodos
AR111813A2 (es) Compuestos y composiciones para el control de nematodos
PE20130588A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BRPI0516323A (pt) construtos de rna
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR048411A1 (es) Metodos para controlar patogenos de plantas que utilizan n-fosfonometilglicina
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
PE20091109A1 (es) Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
AR063899A1 (es) Materiales plasticos
WO2006059247A8 (en) VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
WO2014049447A3 (en) A whole, leech saliva extract

Legal Events

Date Code Title Description
FB Suspension of granting procedure